I-Tirzepatide iyinoveli ye-GIP / GLP-1 ye-receptor agonist yenoveli ebonise isithembiso esikhulu kunyango lwezifo ze-metabolic. Ngokulinganisa izenzo ze-hormone ze-incretin ezimbini zendalo, ziphucula i-insulin secretion, icinezela amanqanaba e-glucagon, kunye nokunciphisa ukutya okutyayo-ngoncedo ngokufanelekileyo ekulawuleni i-glucose yegazi kunye nokukhuthaza ukulahleka kwesisindo.
Ngokwezibonakaliso ezivunyiweyo, i-tirzepatide okwangoku igunyaziswe ukulawula i-glucose yegazi kwizigulane ezinesifo sikashukela sohlobo lwe-2 kunye nokulawula ubunzima bexesha elide kubantu abanokukhuluphala okanye ukukhuluphala. Ukusebenza kwayo kweklinikhi kuxhaswe ngamandla zizifundo ezininzi: uchungechunge lovavanyo lwe-SURPASS lubonise ukuba i-tirzepatide inciphisa kakhulu amanqanaba e-HbA1c kuwo wonke amayeza ahlukeneyo kwaye igqithise unyango olukhoyo olufana ne-semaglutide. Kulawulo lobunzima, iimvavanyo ze-SURMOUNT zazisa iziphumo ezinomdla-ezinye izigulana zafumana phantse i-20% yokuncipha kobunzima bomzimba kunyaka, ukubeka i-tirzepatide njengelinye lawona machiza asebenzayo achasene nokutyeba kwimarike.
Ngaphandle kwesifo seswekile kunye nokutyeba, ukusetyenziswa okunokwenzeka kwe-tirzepatide kuyanda. Ulingo lwezonyango oluqhubekayo luphonononga ukusetyenziswa kwayo ekunyangeni iimeko ezifana ne-non-alcoholic steatohepatitis (NASH), isifo sezintso esingapheliyo, kunye nokusilela kwentliziyo. Ngokucacileyo, kwisigaba sesi-3 solingo lwe-SUMMIT, i-tirzepatide ibonise ukuncipha okukhulu kweziganeko ezinxulumene nokungaphumeleli kwentliziyo phakathi kwezigulana ezinokusilela kwentliziyo kunye neqhezu le-ejection eligciniweyo (HFpEF) kunye nokutyeba, enika ithemba elitsha kwizicelo zonyango ezibanzi.
Ixesha lokuposa: Jul-24-2025